An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma
Authors:
- Manjun LiMLManjun Li
- Melissa K. BennettMBMelissa K. Bennett
- John ToubiaJohn Toubia
- Victoria S. PopeVPVictoria S. Pope
- Melinda N. TeaMTMelinda N. Tea
- Michael S. SamuelMSMichael S. Samuel
- Paul H. AndersonPAPaul H. Anderson
- Briony L. GliddonBGBriony L. Gliddon
- Jason A. PowellJPJason A. Powell
- Stuart M. PitsonStuart M. Pitson
Open Access
- 5 December 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 566-570
Abstract
Summary: While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM.Keywords
Funding Information
- Fay Fuller Foundation
- National Health and Medical Research Council (1156693, 1162954)
- Royal Adelaide Hospital Research Fund
This publication has 15 references indexed in Scilit:
- The genetic landscape of 5T models for multiple myelomaScientific Reports, 2018
- Spectrum and functional validation of PSMB5 mutations in multiple myelomaLeukemia, 2018
- Resistance to proteasome inhibitors and other targeted therapies in myelomaBritish Journal of Haematology, 2018
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma ModelMolecular Cancer Therapeutics, 2013
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaBlood, 2012
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacyBlood, 2012
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorBlood, 2009
- Emerging therapies for multiple myelomaExpert Opinion on Emerging Drugs, 2009
- Self-tolerance of natural killer cellsNature Reviews Immunology, 2006